In Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model

Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01538-19. doi: 10.1128/AAC.01538-19. Print 2020 Feb 21.

Abstract

Nonimmune Aotus monkeys infected with Plasmodium falciparum and Plasmodium vivax were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.5 days, respectively. This in vivo potency and lengthy half-life supports the further development of JPC-3210 as a promising, long-acting blood schizontocidal antimalarial for malaria treatment and prevention.

Keywords: Aotus monkeys; JPC-3210; Plasmodium falciparum; Plasmodium vivax; antimalarial drug discovery; in vitro drug susceptibility; pharmacokinetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antimalarials
  • Aotidae
  • Female
  • Humans
  • Malaria / drug therapy*
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / prevention & control
  • Malaria, Vivax / drug therapy*
  • Malaria, Vivax / prevention & control
  • Male
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / pathogenicity
  • Plasmodium vivax / drug effects
  • Plasmodium vivax / pathogenicity

Substances

  • Antimalarials